STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Karo Bio (STO:KARO) has signed an agreement to acquire the drug research company Tanomed AB, which has developed a unique product for common cold.
The acquisition provides Karo Bio access to a new product to relieve and prevent progression of common cold by reinforcing the body’s own defenses to fight common cold viruses. The patented technology is based on Swedish research in cooperation with University of Umeå where the enzyme glucose oxidase is used in combination with glucose to effectively counteract rhinovirus infections as well as other viral and bacterial pathogens. Several clinical studies show that early treatment prevents or reduces disease progression.
Help employers find you! Check out all the jobs and post your resume.
